Teva's latest Phase III Nuvigil trial fails in depression associated with bipolar 1
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries said it remains committed to its clinical development program for Nuvigil (armodafinil) as adjunct therapy for patients with depression associated with bipolar 1 disorder even though top-line data show that the second (Study 3072) of three Phase III trials has failed to meet primary and secondary endpoints.